|Bid||6.20 x 800|
|Ask||6.25 x 800|
|Day's Range||6.00 - 6.33|
|52 Week Range||5.91 - 11.52|
|Beta (5Y Monthly)||1.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 18, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.60|
If you're looking for a stock with potential to rise 1,000%, you might find it in the coronavirus vaccine and treatment space. Let's take a look at two exciting players working on coronavirus treatments -- and see if they have what it takes to become tomorrow's stock-market winners. Humanigen (NASDAQ: HGEN) shares soared more than 54% in one trading session after the company reported positive results from its investigational monoclonal antibody treatment for hospitalized COVID-19 patients.
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva®, ABC294640) in patients hospitalized with severe COVID-19 pneumonia has received a unanimous recommendation to continue, following a fourth independent Data Safety Monitoring Board (DSMB) safety review. The DSMB's recommendation is based on an analysis of unblinded safety data from the first 255 patients treated for 14 days, extending the total opaganib safety database to approximately 380 patients.
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc., AztraZeneca AB and AstraZenca Pharmaceuticals LP ("AZ") and Nektar Therapeutics ("Nektar") have entered into a settlement and license agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories PVT. LTD. ("MSN") resolving their patent litigation in the U.S. in response to MSN's Abbreviated New Drug Application ("ANDA") seeking approval by the US. Food and Drug Administration ("FDA") to market a generic version of Movantik® (naloxegol).